Theranostic Lipid Nanoparticles for Renal Cell Carcinoma

Abstract

Renal cell carcinoma (RCC) is a common urological malignancy and represents a leading threat to healthcare. Recent years have seen a series of progresses in the early diagnosis and management of RCC. Theranostic lipid nanoparticles (LNPs) are increasingly one of the focuses in this field, because of their suitability for tumor targeting and multimodal therapy. LNPs can be precisely fabricated with desirable chemical compositions and biomedical properties, which closely match the physiological characteristics and clinical needs of RCC. Herein, a comprehensive review of theranostic LNPs is presented, emphasizing the generic tool nature of LNPs in developing advanced micro‐nano biomaterials. It begins with a brief overview of the compositions and formation mechanism of LNPs, followed with an introduction to kidney‐targeting approaches, such as passive, active, and stimulus responsive targeting. With examples provided, a series of modification strategies for enhancing the tumor targeting and functionality of LNPs were discussed. Thereafter, research advances on applications of these LNPs for RCC including bioimaging, liquid biopsy, drug delivery, physical therapy, and gene therapy are summarized and discussed from an interdisciplinary perspective. The final part highlights the milestone achievements of translation medicine, current challenges as well as future development directions of LNPs for the diagnosis and treatment of RCC.This article is protected by copyright. All rights reserved

Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials

“…The ongoing progress in nanotechnology has led to the identification of novel applications for various types of nanomaterials such as natural, synthetic, inorganic, and lipid nanomaterials [ [27] , [28] , [29] ]. Nanomaterials exhibit superior drug delivery and targeting capabilities compared to conventional materials, as well as enhanced functionalization of drug carrier surfaces.…”

A Dual-Recognition Fluorescence Enzyme-Linked Immunosorbent Assay for Specific Detection of Intact Lipid Nanoparticles via a Localized Scaffolding Autocatalytic DNA Circuit Amplifier

“…Lipid nanoparticles (LNPs) are excellent carriers for targeted drug delivery due to their good biocompatibility and high loading capacity. , In addition to being vaccine carriers, , LNPs have other applications, such as genomic drugs , and tumor immunotherapy. , Although an increasing amount of basic research on LNPs has been reported, , clinical applications are still limited by their effectiveness and safety. Once LNPs are introduced into the body, they may be damaged by several adverse factors, leading to LNP rupture.…”